Cite This Page

Citation styles for The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test

APA style

The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test. (2024, January 30). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 12:17, June 4, 2024 from https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877.

MLA style

"The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 30 Jan 2024, 09:24 UTC. 4 Jun 2024, 12:17 <https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 30 January 2024, 09:24 UTC, <https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877> [accessed 4 June 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877 (accessed June 4, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 30, 09:24 UTC [cited 2024 Jun 4]. Available from: https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877.

Bluebook style

The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test, https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877 (last visited June 4, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877",
   note = "[Online; accessed 4-June-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred:

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "The consequence of 6day subcutaneous glucosedependent insulinotropic polypeptide infusion punctually in glycaemic variety inside people together with type 1 diabetes the randomised doubleblind placebocontrolled crossover test --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=The_consequence_of_6day_subcutaneous_glucosedependent_insulinotropic_polypeptide_infusion_punctually_in_glycaemic_variety_inside_people_together_with_type_1_diabetes_the_randomised_doubleblind_placebocontrolled_crossover_test&oldid=626877}",
   note = "[Online; accessed 4-June-2024]"
 }